信号转导和转录激活因子6（STAT6）及磷酸化信号转导和转录激活因子6在淋巴瘤中存在差异表达。

STAT6 and phosphorylated STAT6 are differentially expressed in lymphomas.

作者信息

Karpathiou Georgia, Ferrand Elise, Papoudou-Bai Alexandra, Camy Florian, Honeyman Fressia, Dumollard Jean Marc, Peoc'h Michel

机构信息

Pathology Department, University Hospital of Saint-Etienne, France.

出版信息

Pathol Res Pract. 2022 Jan;229:153697. doi: 10.1016/j.prp.2021.153697. Epub 2021 Nov 23.

DOI:10.1016/j.prp.2021.153697

PMID:34839096

Abstract

BACKGROUND

The STAT6 pathway is implicated in the pathogenesis of various lymphomas; however, its immunohistochemical expression has not been fully investigated. Thus, the aim of this study was to investigate the immunohistochemical expression of the two forms of STAT6, phosphorylated or not, in a series of systemic lymphomas.

MATERIALS AND METHODS

Immunohistochemical expression of two antibodies, STAT6 (clone YE361) and pSTAT6 (clone Y641), which recognise the phosphorylated form of the molecule was studied in 60 lymphomas.

RESULTS

STAT6 expression was cytoplasmic, with 23.3% of the cases showing high expression. pSTAT6 expression was mostly nuclear and found in 45% of the cases. pSTAT6 nuclear expression was associated with the lymphoma type (p < 0.0001), as it was seen mostly in follicular, Hodgkin and angioimmunoblastic T cell lymphomas. STAT6 cytoplasmic expression was also associated with lymphoma type (p = 0.001), as it was mostly found in diffuse large B cell and marginal B cell lymphomas. No association with PD-L1 expression, other clinicopathological data or prognosis was found.

CONCLUSION

The two STAT6 clones are differentially expressed between lymphoma types.

摘要

背景

信号转导和转录激活因子6（STAT6）通路与多种淋巴瘤的发病机制有关；然而，其免疫组化表达尚未得到充分研究。因此，本研究的目的是探讨两种形式的STAT6（磷酸化和非磷酸化）在一系列系统性淋巴瘤中的免疫组化表达。

材料与方法

在60例淋巴瘤中研究了两种抗体STAT6（克隆号YE361）和pSTAT6（克隆号Y641）的免疫组化表达，这两种抗体可识别该分子的磷酸化形式。

结果

STAT6表达位于细胞质中，23.3%的病例呈高表达。pSTAT6表达主要位于细胞核中，见于45%的病例。pSTAT6核表达与淋巴瘤类型相关（p < 0.0001），主要见于滤泡性、霍奇金和血管免疫母细胞性T细胞淋巴瘤。STAT6细胞质表达也与淋巴瘤类型相关（p = 0.001），主要见于弥漫性大B细胞和边缘区B细胞淋巴瘤。未发现与程序性死亡受体配体1（PD-L1）表达、其他临床病理数据或预后相关。